SCHEMBL7034065

SCHEMBL7034065

Cc1ccccc1C(=S)c1ccc(Nc2cncc3ccccc23)cc1Cl

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPK14 Q16539 11/20 0.49
MAPK13 O15264 10/20 0.49
MAPK12 P53778 10/20 0.49
MAPK11 Q15759 10/20 0.49
ADRA2A P08913 1/20 0.45
ADRA2B P18089 1/20 0.45
ADRA2C P18825 1/20 0.45
ADRA1A P35348 1/20 0.45
ALDH1A1 P00352 4/20 0.39
SMN1; SMN2 Q16637 4/20 0.39
KMT2A Q03164 3/20 0.39
MAPT P10636 3/20 0.39
MALT1 Q9UDY8 1/20 0.39
MEN1 O00255 2/20 0.38
TRPV1 Q8NER1 1/20 0.36
PTK6 Q13882 1/20 0.36
KDM4E B2RXH2 2/20 0.35
LMNA P02545 1/20 0.35
HPGD P15428 1/20 0.35
CASP3 P42574 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7035323 0.91 ADRA2A (0.43) MAPK14MAPK13MAPK12MAPK11ADRA2A
SCHEMBL7030779 0.90 ADRA2A (0.44) MAPK14MAPK13MAPK12MAPK11ADRA2A
SCHEMBL7033598 0.90 MAPK14 (0.48) MAPK14MAPK13MAPK12MAPK11ADRA2A
SCHEMBL7039905 0.89 ALDH1A1 (0.52) MAPK14MAPK13MAPK12MAPK11ALDH1A1
SCHEMBL7040319 0.88 MAPT (0.42) MAPK14MAPK13MAPK12MAPK11ADRA2A
SCHEMBL7036407 0.87 MAPK14 (0.67) MAPK14MAPK13MAPK12MAPK11ADRA2A
SCHEMBL7035666 0.85 MAPK14 (0.47) MAPK14MAPK13MAPK12MAPK11ADRA2A
SCHEMBL7515617 0.85 TRPV1 (0.40) MAPK14MAPK13MAPK12MAPK11ADRA2A
SCHEMBL7030742 0.83 MAPK14 (0.55) MAPK14MAPK13MAPK12MAPK11KMT2A
SCHEMBL5174459 0.81 MAPK14 (0.71) MAPK14MAPK13MAPK12MAPK11MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6432962-B2 Benzophenones as inhibitors of IL-1β and TNF-α LEO PHARMACEUTICAL PRODUCTS LTD. A/S (DK) 2002-08-13 US claimed
EP-1289958-A2 BENZOPHENONES AS INHIBITORS OF IL-1$g(b) AND TNF-$g(a) Leo Pharma A/S (DK) 2003-03-12 EP disclosed
US-6432962-B2 Benzophenones as inhibitors of IL-1β and TNF-α LEO PHARMACEUTICAL PRODUCTS LTD. A/S (DK) 2002-08-13 US disclosed
US-20020016347-A1 Benzophenones as inhibitors of IL-1beta and TNF-alpha LEO PHARMACEUTICAL PRODUCTS LTD. A/S (DK) 2002-02-07 US disclosed
WO-2001090074-A2 BENZOPHENONES AS INHIBITORS OF IL-1β AND TNF-$g(a) LEO PHARMA A/S (DK) 2001-11-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020016347-A1 Benzophenones as inhibitors of IL-1beta and TNF-alpha IL1B, IL1A, NFKBIA MAPK14 625/4885MAPK13 1908/4885MAPK12 1184/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.